Skip to content

Dossier · PLMR · Dormant

PLMR · Palomar Holdings, Inc. · Stock research

Last analysed ·

Current thesis

Specialty-P&C compounder re-rating: three Overweight/Outperform PT raises to $165–167 in 12 days (KBW 07-08, Piper 07-15, JPM 07-20) drove a breakout to new highs, +25% in a month on 42% GWP growth. Narrative re-accelerating and sell-side now clustered — but the 2026-08-03 Q2 print is a binary 8 days out.

Invalidation trigger

A weekly close below $125 negates the July breakout and puts price back inside the pre-breakout range (the deeper post-Q1 base off the $100.81 low sits near $120); secondarily, a Q2 (2026-08-03) print with GWP growth decelerating below ~30% or the combined ratio pushing toward 90% breaks the profitable-growth frame.

Thesis status

Open commitment catalyst 6d agoscored if the trigger above fires How this is scored →

Latest analysis and events for PLMR —

As of 2026-07-26, orbyd's latest analysis for Palomar Holdings, Inc. (PLMR): Specialty-P&C compounder re-rating: three Overweight/Outperform PT raises to $165–167 in 12 days (KBW 07-08, Piper 07-15, JPM 07-20) drove a breakout to new highs, +25% in a month on 42% GWP growth. Narrative re-accelerating and sell-side now clustered — but the 2026-08-03 Q2 print is a binary 8 days out.

Invalidation trigger: A weekly close below $125 negates the July breakout and puts price back inside the pre-breakout range (the deeper post-Q1 base off the $100.81 low sits near $120); secondarily, a Q2 (2026-08-03) print with GWP growth decelerating below ~30% or the combined ratio pushing toward 90% breaks the profitable-growth frame.

Most recent dated event on file: — catalyst 6d ago.

Current Thesis

Palomar is a specialty property-and-casualty compounder in the middle of a re-rating. The Q1 2026 print (2026-05-06) showed gross written premium up 42.4% to $629.8M and management lifting the FY26 adjusted-income guide to $262–278M at 20%+ adjusted ROE. Two weeks ago the tape was stalled 8% under its highs with sell-side split; that has reversed. Three Overweight/Outperform price-target raises to $165–167 landed in twelve days, the stock broke out to new highs, and it is up roughly 25% over the trailing month to ~$140.80. The specialty-insurance narrative is re-accelerating and the sell-side is now clustering behind it rather than diverging. The complication: the 2026-08-03 Q2 report is a binary eight days out, so a fresh entry here buys an extended, re-rated name directly into an earnings print.

Bullish and bearish views on Palomar Holdings, Inc.

The model's bull view on Palomar Holdings, Inc. (PLMR), in brief: GWP +42.4% YoY to $629.8M in Q1 2026 (from $442.2M), broad-based across Casualty, Inland Marine & Property, Crop, and Surety & Credit — reported 2026-05-06. The bear view: GAAP net income was flat YoY at $42.9M ($1.57 diluted EPS) in Q1 2026; the growth story lives entirely in the adjusted line. Both cases follow in full.

Bull Case

  • GWP +42.4% YoY to $629.8M in Q1 2026 (from $442.2M), broad-based across Casualty, Inland Marine & Property, Crop, and Surety & Credit — reported 2026-05-06.
  • Adjusted net income +23.1% to $63.1M ($2.31 adjusted diluted EPS) in Q1; FY26 adjusted-income guide raised to $262–278M (~24% growth at the midpoint), adjusted ROE above the 20% "Palomar 2X" bar.
  • Sell-side flipped from split to clustered-bullish in twelve days: KBW (Meyer Shields) Outperform, PT $166 on 2026-07-08; Piper Sandler upgraded to Overweight, PT $165 on 2026-07-15; J.P. Morgan (Singzon) raised to $167 from $150 on 2026-07-20 — a 14-day upgrade cluster is narrative-acceleration confirmation, not a single-analyst call.
  • Price broke the multi-month consolidation and is back near the 52-week high (~$145–147.62 vs a $100.81 low), +25.4% over the trailing month, +4.1% intraday on the 2026-07-20 JPM raise — momentum bid is present where two weeks ago there was none.
  • Franchise de-risking off earthquake concentration continues: Casualty GWP grew 161% in 2024, Crop broadened via the Advanced AgProtection deal (Q2 2025) and the Gray acquisition closed 2026-01-31.
  • $200M buyback authorized 2026-05-06, running through 2028-05-06 — a standing bid on any pullback.

Bear Case

  • GAAP net income was flat YoY at $42.9M ($1.57 diluted EPS) in Q1 2026; the growth story lives entirely in the adjusted line.
  • Combined ratio deteriorated to 84.5% from 73.1% a year earlier and the loss ratio jumped to 33.3% as the mix shifts toward higher-loss-ratio Casualty and Crop — underwriting margin is compressing while premium grows.
  • The stock has already traveled most of the analyst re-rating: at ~$140.80 against $165–167 targets, roughly 18% of upside remains, and a name +25% in a month into a binary print carries pulled-forward risk.
  • Evercore ISI sits at $152 (cut 2026-07-10), the laggard of the cluster, flagging that not every desk buys the acceleration.
  • Cat-exposed book (earthquake, wind) carries tail risk into Atlantic hurricane season; a large event historically forced reinsurance-line repricing.
  • Low-beta name (0.41) — when the momentum bid fades, there is little natural buying to catch a post-print air pocket.

Setup & Price Structure

  • Last ~$140.80, near the 52-week high (~$145.29 recent, $147.62 prior spike) and ~40% above the 52-week low of $100.81; +25.4% over the trailing month.
  • Structure has flipped from the July digestion range to a confirmed breakout on the analyst-upgrade cluster — strength is now the setup, but the eight-day runway to the print caps how much a fresh buyer can lean in.
  • Valuation ~20x trailing / ~14x forward on a ~$3.7B market cap (~26.5M shares); the multiple re-rated as targets moved, so this is no longer a "cheap and dead" tape.
  • The reclaimed breakout base sits near $125–130; the deeper post-Q1 floor and the base off the $100.81 low is ~$120. Losing the former negates the July move, losing the latter breaks the multi-month structure.

Catalyst Calendar (next 30 days)

  • Ongoing — $200M buyback (through 2028-05-06) provides support on pullbacks.
  • Aug–Oct — Atlantic hurricane season and reinsurance-pricing headlines can move the earthquake/wind-exposed lines independent of the equity tape.

Elapsed catalysts

  • 2026-08-03 — Q2 2026 earnings (confirmed). The binary: is GWP growth still 40%+, does the combined ratio stabilize off the 84.5% Q1 mark, and does the FY26 guide move again. A blackout window applies inside three trading days (~from 2026-07-29). (passed 6d ago)

What Would Change Our Mind

  • A weekly close below $125 negates the July breakout and puts price back inside the pre-breakout range; a weekly close below $120 breaks the post-Q1 base built off the $100.81 low.
  • A Q2 print (2026-08-03) showing GWP growth decelerating below ~30% or the combined ratio pushing toward 90% would break the profitable-growth frame regardless of price.
  • Reversal of the analyst cluster — a downgrade or target cut following the print — would remove the confirmation that turned this from digestion into a breakout.
  • Theme flipping to saturated: if the specialty-insurance re-rating draws in late retail and the peer group stalls together, the momentum bid is spent.

Correlation Notes

  • Trades with the specialty/E&S P&C complex — Kinsale (KNSL), RLI, Skyward (SKWD), ProAssurance — more than with the broad market; the group re-rates together on insurance-pricing-cycle strength.
  • Sensitive to catastrophe and Atlantic-hurricane-season headlines given the earthquake/wind book; a major cat event decouples it from the P&C group to the downside.
  • Float income ties partial sensitivity to Treasury yields; higher-for-longer supports investment income, a rate cut trims it.
  • Low beta (0.41) means it lags broad-market risk-on rallies and is driven more by name-specific catalysts (the print, buyback, analyst cluster) than by index beta — a stock-picker's tape, not an index proxy.

Notes

  • Analyst PTs splitting: KBW $166 (raise, 07-08) vs Evercore $152 (cut, 07-10), JPM $150, Piper $132.
  • $200M buyback authorized 2026-05-06 through 2028-05-06 — standing bid on weakness.
  • Q2 2026 earnings confirmed 2026-08-03 — binary print; treat inside 3 trading days (~from 2026-07-29) as blackout.
  • Theme tag: specialty P&C (earthquake, casualty, crop, inland marine, surety), NOT managed-care/health-services — prior mis-tag corrected.
  • Combined ratio 84.5% in Q1 2026 vs 73.1% a year earlier — underwriting margin compressing as mix shifts to Casualty/Crop; watch the Q2 combined ratio.
  • Analyst cluster flipped bullish in July: KBW $166 (07-08), Piper upgrade to Overweight $165 (07-15), JPM $167 (07-20); Evercore laggard at $152 (07-10).
  • Cat-exposed book (earthquake, wind) into Atlantic hurricane season Aug–Oct — a major event can decouple it from the P&C group to the downside.
  • Beginner-trap watch: +25% in a month, near 52-week highs, binary print 8 days out — the clean entry was the July base, not a chase into the print.

Related · shared themes

HUM

Humana Inc.

Post-print floor held: the 2026-08-05 undercut to $353.69 closed green on CVS's Aetna guide raise, and 2026-08-07 closed $385.00 (+4.84%), back above the 50-day of $374.23 and the highest close since 07-28. Morgan Stanley's 08-05 upgrade retired the $249 bear target, but the ≥3% 2028 MA margin claim stays unquantified for 2027 and no company-dated financial event is confirmed inside 30 days.

MEDIUM

RXO

RXO, Inc.

Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.

MEDIUM

XMTR

Xometry, Inc.

Q2 on 2026-08-04 cleared every self-set number — revenue $229.3M (+41%), marketplace +45%, Adj EBITDA $14.1M — and the new CEO raised FY2026 growth to 33–34% from 27–28%. Price took three sessions to agree, closing $93.15 on 08-07 back above the $90.65 50-day, still under the $106.08 July high.

MEDIUM

CNC

Centene Corporation

Post-print recovery extended: $65.77 close on 2026-08-07 (+2.45%), above the 20-day and 50-day levels marked on 08-04, with the $69.36 52-week high in view. Two dated events inside four sessions — CMS's 3:00pm EDT 2026-08-12 PY2027 rate lock (HealthCare.gov states only; SBE states run to 10-15) and the 08-13 $500M par redemption. Theme still SATURATED: eight post-print target raises, zero cuts, consensus $71.67 scored at 8.97% upside.

LOW